Dasatinib (BMS-35482) Interacts Synergistically With Docetaxel, Gemcitabine, Topotecan, and Doxorubicin in Ovarian Cancer Cells With High SRC Pathway Activation and Protein Expression

International Journal of Gynecological Cancer - United Kingdom
doi 10.1097/igc.0000000000000056
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Paclitaxel and Ceramide Synergistically Induce Cell Death With Transient Activation of EGFR and ERK Pathway in Pancreatic Cancer Cells

Oncology Reports
MedicineCancer ResearchOncology
2006English

Topotecan in Ovarian Cancer

Oncologist
Cancer ResearchMedicineOncology
1997English

Topotecan Synergizes With CHEK1 (CHK1) Inhibitor to Induce Apoptosis in Ovarian Cancer Cells

BMC Cancer
Cancer ResearchOncologyGenetics
2015English

Combination Therapy With Gossypol Reveals Synergism Against Gemcitabine Resistance in Cancer Cells With High BCL-2 Expression

PLoS ONE
Multidisciplinary
2012English

Role of SRC Expression and Activation in Human Cancer

Oncogene
Cancer ResearchGeneticsMolecular Biology
2000English

A Phase I Trial of Dasatinib, an SRC-Family Kinase Inhibitor, in Combination With Paclitaxel and Carboplatin in Patients With Advanced or Recurrent Ovarian Cancer

Clinical Cancer Research
Cancer ResearchOncology
2012English

Activity of the Multikinase Inhibitor Dasatinib Against Ovarian Cancer Cells

British Journal of Cancer
Cancer ResearchOncology
2009English

Phase I Trial of Weekly Topotecan and Gemcitabine in Patients With Solid Tumors

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2009English

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy